STOCK TITAN

Alzamend Neuro Inc - ALZN STOCK NEWS

Welcome to our dedicated news page for Alzamend Neuro (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alzamend Neuro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alzamend Neuro's position in the market.

-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.8%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
none
Alzamend Neuro Inc

AMEX:ALZN

ALZN Rankings

ALZN Stock Data

5.23M
4.83M
29.64%
5.45%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tampa

About ALZN

alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease, bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat alzheimer’s.